tiprankstipranks
Trending News
More News >
Anika Therapeutics (ANIK)
NASDAQ:ANIK
US Market

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Compare
161 Followers
See the Price Targets and Ratings of:

ANIK Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Anika
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ANIK Stock 12 Month Forecast

Average Price Target

$21.33
▲(89.26%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is $21.33 with a high forecast of $24.00 and a low forecast of $19.00. The average price target represents a 89.26% change from the last price of $11.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","20":"$20","27":"$27","16.5":"$16.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,16.5,20,23.5,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"May<br/>2024","9":"Nov<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.46,15.193846153846154,15.927692307692308,16.661538461538463,17.395384615384614,18.12923076923077,18.863076923076925,19.596923076923076,20.33076923076923,21.064615384615387,21.798461538461538,22.532307692307693,23.26615384615385,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.46,14.98846153846154,15.516923076923078,16.045384615384616,16.573846153846155,17.102307692307694,17.630769230769232,18.159230769230767,18.68769230769231,19.216153846153844,19.744615384615386,20.27307692307692,20.80153846153846,{"y":21.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.46,14.80923076923077,15.15846153846154,15.507692307692308,15.856923076923078,16.206153846153846,16.555384615384614,16.904615384615386,17.253846153846155,17.603076923076923,17.95230769230769,18.301538461538463,18.65076923076923,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.64,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1682899200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.49,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.53,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$24.00Average Price Target$21.33Lowest Price Target$19.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ANIK
TipRanks AITipRanks
Not Ranked
TipRanks
$11
Hold
-2.40%
Downside
Reiterated
05/15/25
Anika Therapeutics is under financial strain due to declining revenues and profitability issues, reflected in its stock's bearish technical indicators and valuation challenges. Despite this, strategic moves like the sale of Parcus Medical and revenue growth in specific channels offer some positive outlook for future positioning.
Sidoti
$28$24
Buy
112.95%
Upside
Reiterated
05/28/25
Sidoti Sticks to Their Buy Rating for Anika Therapeutics (ANIK)
Barrington Analyst forecast on ANIK
Michael PetuskyBarrington
Barrington
$20$19
Buy
68.59%
Upside
Reiterated
05/12/25
Anika Therapeutics selloff provides entry point, says BarringtonAnika Therapeutics selloff provides entry point, says Barrington
B.Riley Financial Analyst forecast on ANIK
Anderson SchockB.Riley Financial
B.Riley Financial
$21
Buy
86.34%
Upside
Initiated
04/17/25
B.Riley starts Anika Therapeutics (ANIK) at BuyB.Riley analyst Anderson Schock initiates coverage on Anika Therapeutics (NASDAQ: ANIK) with a Buy rating and a price target of $21.00.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ANIK
TipRanks AITipRanks
Not Ranked
TipRanks
$11
Hold
-2.40%
Downside
Reiterated
05/15/25
Anika Therapeutics is under financial strain due to declining revenues and profitability issues, reflected in its stock's bearish technical indicators and valuation challenges. Despite this, strategic moves like the sale of Parcus Medical and revenue growth in specific channels offer some positive outlook for future positioning.
Sidoti
$28$24
Buy
112.95%
Upside
Reiterated
05/28/25
Sidoti Sticks to Their Buy Rating for Anika Therapeutics (ANIK)
Barrington Analyst forecast on ANIK
Michael PetuskyBarrington
Barrington
$20$19
Buy
68.59%
Upside
Reiterated
05/12/25
Anika Therapeutics selloff provides entry point, says BarringtonAnika Therapeutics selloff provides entry point, says Barrington
B.Riley Financial Analyst forecast on ANIK
Anderson SchockB.Riley Financial
B.Riley Financial
$21
Buy
86.34%
Upside
Initiated
04/17/25
B.Riley starts Anika Therapeutics (ANIK) at BuyB.Riley analyst Anderson Schock initiates coverage on Anika Therapeutics (NASDAQ: ANIK) with a Buy rating and a price target of $21.00.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Anika Therapeutics

1 Month
xxx
Success Rate
14/27 ratings generated profit
52%
Average Return
-1.06%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.85% of your transactions generating a profit, with an average return of -1.06% per trade.
3 Months
xxx
Success Rate
15/27 ratings generated profit
56%
Average Return
-2.05%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of -2.05% per trade.
1 Year
Michael PetuskyBarrington
Success Rate
5/27 ratings generated profit
19%
Average Return
-15.64%
reiterated a buy rating last month
Copying Michael Petusky's trades and holding each position for 1 Year would result in 18.52% of your transactions generating a profit, with an average return of -15.64% per trade.
2 Years
xxx
Success Rate
1/27 ratings generated profit
4%
Average Return
-31.97%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 3.70% of your transactions generating a profit, with an average return of -31.97% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANIK Analyst Recommendation Trends

Rating
Oct 24
Nov 24
Mar 25
Apr 25
May 25
Strong Buy
0
1
2
2
3
Buy
3
2
2
2
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
4
4
5
In the current month, ANIK has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ANIK average Analyst price target in the past 3 months is 21.33.
Each month's total comprises the sum of three months' worth of ratings.

ANIK Financial Forecast

ANIK Earnings Forecast

Next quarter’s earnings estimate for ANIK is -$0.26 with a range of -$0.35 to -$0.13. The previous quarter’s EPS was -$0.06. ANIK beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.97% of the time in the same period. In the last calendar year ANIK has Outperformed its overall industry.
Next quarter’s earnings estimate for ANIK is -$0.26 with a range of -$0.35 to -$0.13. The previous quarter’s EPS was -$0.06. ANIK beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.97% of the time in the same period. In the last calendar year ANIK has Outperformed its overall industry.

ANIK Sales Forecast

Next quarter’s sales forecast for ANIK is $27.03M with a range of $26.60M to $27.50M. The previous quarter’s sales results were $26.17M. ANIK beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year ANIK has Outperformed its overall industry.
Next quarter’s sales forecast for ANIK is $27.03M with a range of $26.60M to $27.50M. The previous quarter’s sales results were $26.17M. ANIK beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year ANIK has Outperformed its overall industry.

ANIK Stock Forecast FAQ

What is ANIK’s average 12-month price target, according to analysts?
Based on analyst ratings, Anika Therapeutics’s 12-month average price target is 21.33.
    What is ANIK’s upside potential, based on the analysts’ average price target?
    Anika Therapeutics has 89.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ANIK a Buy, Sell or Hold?
          Anika Therapeutics has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Anika Therapeutics’s price target?
            The average price target for Anika Therapeutics is 21.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $24.00 ,the lowest forecast is $19.00. The average price target represents 89.26% Increase from the current price of $11.27.
              What do analysts say about Anika Therapeutics?
              Anika Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of ANIK?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis